Clinical TrialJun 25, 2026, 04:17 PM
PRF Technologies Reports Expanded Preclinical Results for PRF-110
AI Summary
PRF Technologies Ltd. announced expanded preclinical results for its lead product candidate, PRF-110, in a head-to-head comparison with ZYNRELEF. The study showed PRF-110 had comparable analgesic efficacy, slower absorption, and enhanced local tissue retention. These findings reinforce PRF-110's potential as a long-acting, single-administration post-operative analgesic, aiming to reduce opioid use.
Key Highlights
- PRF-110 showed comparable analgesic efficacy to ZYNRELEF in reducing mechanical sensitivity.
- PRF-110 exhibited a slower absorption rate compared to ZYNRELEF.
- PRF-110 demonstrated enhanced retention in local tissue with higher local tissue exposure (Cmax).
- Both PRF-110 and ZYNRELEF showed sustained systemic and local drug levels.
- The study was conducted in a validated porcine post-operative pain model.
Price Impact
More from PRFX